I've been tracking this FDA peptide story since early July, from the staff briefing that recommended against BPC 157 all the way through this week's final votes, and it finally has an ending. Six of the seven peptides under review just got the advisory committee's blessing. One did not. Here's exactly what that means, and, more importantly, what it doesn't.
Over two days, the FDA's Pharmacy Compounding Advisory Committee voted on seven peptides being considered for the 503A Bulks List, the list that determines what compounding pharmacies can legally manufacture. Thursday brought votes for BPC 157, KPV, TB 500, and MOTS c. Friday closed the hearing with three more votes: 7 to 5, with one abstention, to recommend epitalon for insomnia. 8 to 5 to recommend semax for cerebral ischemia, migraine, and trigeminal neuralgia. And 6 to 7, with one abstention, against emideltide for opioid withdrawal, chronic insomnia, and narcolepsy. The final tally across both days: six of the seven peptides reviewed cleared the committee, all against the explicit recommendation of the FDA's own career scientific staff.
Two independently reported outlets, STAT News and RAPS Regulatory Focus, agree exactly on all three Friday vote tallies, cross checked against the official FDA meeting agenda. What's notable is how the committee got there. Pharmacist David Pope voted yes on epitalon the same day he voted no on emideltide, citing emideltide's potentially dangerous downstream consequences. Committee member Kevin Zacharoff and others pointed to weaker and older evidence for emideltide specifically, with one noting the last relevant study was 30 years old. That's real evidence the panel was weighing each substance on its own record, not simply approving the whole slate. Still, the FDA's own briefing documents for both days stated there was insufficient safety and efficacy evidence for every single substance discussed, emideltide included.
This is still a non binding advisory recommendation, not an approval. The FDA can, and sometimes does, override its own advisory committees in either direction, and formal rulemaking has historically taken 12 to 24 months. The evidence base for all six recommended peptides is unchanged by this vote, still animal studies, small uncontrolled pilot data, or, for semax, foreign market use without US trials, not large randomized controlled trials. Several committee members who voted no across multiple substances cited poor characterization and a significant lack of safety data as recurring concerns, and that dissent is part of the official record, not a footnote. Both sourced articles are secondary journalism on the vote, not FDA's own published tally, which typically posts weeks after a meeting like this.
If you've seen "BPC 157 is legal now" circulating this week, that's not quite right. What actually happened is that six increasingly popular peptides, BPC 157, KPV, TB 500, MOTS c, epitalon, and semax, are one non binding advisory vote closer to legal compounding pharmacy access, while emideltide is not. Nothing about what you can legally buy changed today, and the human evidence for these peptides hasn't gotten any stronger just because a committee voted. Worth watching for is the FDA's actual rulemaking decision, which is still 12 to 24 months out at minimum.
Over two days, the Pharmacy Compounding Advisory Committee voted on seven peptides for the 503A Bulks List. Thursday brought votes for BPC 157, KPV, TB 500, and MOTS c. Friday closed with a 7 to 5 vote recommending epitalon for insomnia, an 8 to 5 vote recommending semax for migraines and related conditions, and a 6 to 7 vote against emideltide for opioid withdrawal, insomnia, and narcolepsy. Six of the seven peptides reviewed were recommended.
No. This is a non binding advisory recommendation, not an approval. The FDA still has to complete formal rulemaking, which has historically taken 12 to 24 months, and the agency can decline to follow its own committee's recommendation entirely. Nothing about what is legally available to buy changed today.
Committee members who voted no cited weaker and older evidence, with one committee member noting the last relevant study on emideltide was 30 years old, along with safety concerns specific to its proposed use for opioid withdrawal. Pharmacist David Pope voted yes on epitalon the same day he voted no on emideltide, citing its potentially dangerous downstream consequences, which suggests the panel was weighing each substance on its own record rather than approving the whole slate at once.
Get the Daily Signal in your inbox each morning, verified and no hype, before you even open your phone.